Search our team at AdventHealth Research Institute
-
NCT06072781
VS-6766-301/GOG-3097 A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main aims of this clinical study are to: Find out if the combination of avutometinib (VS-6766) and defactinib is better at prolonging the time it takes for LGSOC to grow compared to standard of...
-
NCT05281471
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime Study
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaYou are invited to take part in a research study. This research study is studying Olvi-Vec as a possible treatment for platinum-resistant or platinum-refractory ovarian cancer including fallopian tube...
-
Pilot Feasibility Study of the Interplay between the Host Gut Microbiome and Efficacy of Treatment for Epithelial Ovarian Cancer Patients Receiving IMmunotherapy
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis research is being done to see if your gut microbiome (microorganisms that live in the gut) could help as a biomarker of clinical response to immunotherapy.
-
NCT06819007
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer” GOG 3112/ DSI-T-DXd ENHERTU (DO-01); DESTINY-Ovarian01 (DO-01)] DS8201-772
This study is not currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study consists of two parts: Part 1 (safety run-in) and Part 2 (randomized part [like the flip of a coin]). The purpose of Part 1 is to learn more about the safety and tolerability of the...
-
NCT04625270
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC).
This study is not currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main aims of this clinical study are to: (a) Find out if the best course of study treatment is to take either VS-6766 alone (monotherapy) or to take VS-6766 together (in combination) with...